Daniel Morales on Muck Rack

Daniel Morales

As seen in: Nature, Medium, The New York Times, The Startup, Color Research & Application, Wiley Online Library, heart, MDPI, JAMA (The Journal of the American Medical Association), The Lancet, Towards Data Science and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Daniel

Contact Daniel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Incentives, Evidence, and Reminders for Bureaucrats: Overcoming Barriers to Policy Scale Up

|
By Patrick Agte, Daniel Morales, Christopher A. Neilson
| National Bureau of Economic Research
This project would not have been possible without the support of Julio Valeirón and the research team at IDEICE. We thank the Ministerio de Educación (MINERD) of the Dominican Republic and IDEICE for facilitating joint work between government agencies that produced the data from the Dominican Republic used in this study.
Open in Who Shared Issue with article?

Venous and arterial thromboembolic events after COVID-19 during the Omicron period in three European countries

|
By Xintong Li, Annika M Jödicke, Albert Prats-Uribe, Antonella Delmestri, Katia M Verhamme, Mees Mosseveld, James T Brash, Dina Vojinovic, Anna Palomar-Cros, Laura Crespo, Talita Duarte-Salles, Marek Oja, Raivo Kolde, Edward Burn, Denise Umuhire, Daniel Morales, Martí Català
| Nature
Abstract Patients with earlier SARS-CoV-2 variants are at increased risk of venous and arterial thromboembolic (VTE, ATE) events. Here we aimed to contextualise the incidence of thromboembolic events among patients with COVID-19 during the Omicron period. We conducted a population-based cohort study using electronic health records from the UK (CPRD GOLD), the Netherlands (IPCI), and Spain (SIDIAP) within the DARWIN EU® network.
Open in Who Shared Issue with article?

Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetes

|
By Chungsoo Kim, Fan Bu, Clair Blacketer, Anna Ostropolets, Talita Duarte-Salles, Benjamin Viernes, Thomas Falconer, Andrea Pistillo, Jing Li, Can Yin, Mui Van Zandt, Paul Nagy, Akihiko Nishimura, Evan Minty, Seng Chan You, Mitsuaki Sawano, Shoko Sawano, Ja Young Jeon, Arya Aminorroaya, Lovedeep S Dhingra, Aline F Pedroso, Phyllis Thangaraj, David A. Dorr, Nicole Pratt, Kenneth K. C. Man, Wallis C. Y. Lau, Daniel Morales, Rohan Khera, Martijn J Schuemie, Patrick Ryan, George Hripcsak, Harlan M. Krumholz, Marc A. Suchard, Yuan Lu
| Nature
Abstract As prescribing of newer antihyperglycemic agents expands, there remains limited comparative safety data for older adults—a population particularly vulnerable to adverse drug events and underrepresented in clinical trials. We conduct a multinational cohort study using nine databases from the U.S. and Europe. Among adults aged ≥65, we compare eighteen safety outcomes across four classes of second-line antihyperglycemic agents.
Open in Who Shared Issue with article?
See all 43 licensed articles (46 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Daniel

Contact Daniel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified